Elanco Animal Health: Will The Growth of Zenrelia in the Veterinary Clinic Market Help Build A Competitive Edge & Expand Market Share?

Elanco Animal Health’s fourth quarter 2024 presentation indicates the company is progressing towards its strategic imperatives while grappling with several ongoing challenges. The company’s revenue grew by 4% on an organic constant currency basis, marking the sixth consecutive quarter of revenue growth. This was driven by the company’s dual businesses: Pet Health and Farm Animal. The Pet Health division showed robust growth, with international Pet Health increasing by 11% in constant currency, notably through the success of products like Adtab and Seresto. The U.S. Pet Health division also posted a 2% increase, supported by initiatives like the successful launch of Zenrelia. The diverse geographic growth across the top markets further reinforces Elanco’s strong market presence.